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Abstract
Background: Biomarkers of exposure to Plasmodium falciparum would be a useful tool for the assessment of malaria burden
and analysis of intervention and epidemiological studies. Antibodies to pre-erythrocytic antigens represent potential
surrogates of exposure.
Methods and Findings: In an outbreak cohort of U.S. Marines deployed to Liberia, we modeled pre- and post-deployment
IgG against P. falciparum sporozoites by immunofluorescence antibody test, and both IgG and IgM against the P. falciparum
circumsporozoite protein by enzyme-linked immunosorbant assay. Modeling seroconversion thresholds by a fixed ratio,
linear regression or nonlinear regression produced sensitivity for identification of exposed U.S. Marines between 58–70%
and specificities between 87–97%, compared with malaria-naı ¨ve U.S. volunteers. Exposure was predicted in 30–45% of the
cohort.
Conclusion: Each of the three models tested has merits in different studies, but further development and validation in
endemic populations is required. Overall, these models provide support for an antibody-based surrogate marker of
exposure to malaria.
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Introduction
Assessment of malaria burden is critical for the evaluation of
malaria control measures. We currently lack tools for discrimina-
tion of host exposure to Plasmodium falciparum parasites. In assess-
ment of interventions, correct classification of ‘‘immune’’ and
‘‘unexposed’’ cohorts is important for interpretation of results [1].
Biomarkers of exposure could mitigate classification error and
facilitate clinical trial designs [2].
Antibody responses to blood stage parasites have been
effectively modeled as a tool for estimating transmission intensity
in endemic populations [3,4] and support the use of antibodies as
biomarkers of exposure. However, these models do not discrim-
inate exposure to parasite inoculum (sporozoites) from blood stage
parasites, the former being especially applicable to assessment of
interventions that reduce or prevent blood stage infections or
parasite transmission. Antibody responses to pre-erythrocytic
(sporozoite/liver) antigens represent potential markers of expo-
sure. These antigens have been shown to reflect exposure across
varying transmission intensities [5], and travelers to endemic areas
often show high levels of sporozoite-specific antibodies [6]. In
particular, the circumsporozoite protein (CSP) is an ideal target
due to its pronounced expression from point of inoculation to
residency in hepatocytes [7]. In a recent trial of experimental
infections in humans, 80% of naı ¨ve volunteers inoculated with
sporozoites seroconverted with antibodies against sporozoite
antigens, in particular against CSP [8]. However, the broad use
of CSP as a biomarker may be limited by the variability in CSP-
specific antibody reactivity following exposure in children [9], and
across age groups and transmission settings [10]. Low prevalence
antibodies to CSP in areas of unstable transmission suggest that
persistent antigen exposure is required to maintain antibody levels
[11]. Indeed, recent studies show that B cell memory to malaria
antigens is slowly produced and wanes without re-exposure [12].
Antibody half-life following acute infection varies from a couple of
weeks to several months, but generally decay rapidly [13].
Antibody decay has been observed to be notably faster in very
young children compared to older children, perhaps due to
intrinsic differences in the generation of short-lived and long-lived
plasma cells with age [14]. In infants, short peaks of antibody
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21826responses to the blood stage antigen MSP-1 observed during the
first year of life did not appear to be maintained at higher post-
infection levels than pre-infection [15]. Conversely, a study in
Thailand showed that malaria-specific B-cell memory and
antibody production may persist for years following infection
[16]. Interestingly, antibody prevalence in a low-transmission
region of Peru persisted through the 4-month non-transmission
season, although it was noted that children responded more slowly
than adults [17]. These findings demonstrate B cell memory
capacity may be both age-dependent and influenced by exposure.
In Mali, a population of memory B cells expressing inhibitory
receptors and responding poorly to mitogen stimulation was
expanded in individuals with chronic parasite exposure [18].
‘‘Atypical’’ memory B cells were also observed at lower levels in
Peru and correlated with the lower transmission intensity [19].
Neither the function or causal association with malaria has been
established for atypical B cells, but they may be indicative of the
suboptimal antibody generation and maintenance observed in
areas of high malaria transmission. These observations suggest that
generation and decay of immunological memory is subject to a
highly complex immunoepidemiology.
To date, there is no surrogate marker of exposure to the bite of
infected mosquitoes, and modeling data that reflect natural
exposure is difficult. Henceforth, infection and exposure refer to
inoculum of sporozoites from the bite of infected mosquitoes,
regardless of resulting blood stage infection. In this study, we
examine longitudinal antibody responses during a high incidence
outbreak of P. falciparum malaria among U.S. Marines deployed to
Liberia from August to October, 2003 [20]. Although the exact
level of exposure is undefined, this cohort of Marines provides
a unique opportunity to study antibody acquisition following
exposure. Another study of military personnel after deployment to
a malaria endemic area reported high antibody prevalence to pre-
erythrocytic antigens that demonstrated exposure [21]. In this
study, we aimed to describe antibody responses to the immuno-
dominant sporozoite surface antigen, the CSP, and to the whole
sporozoite, and to propose longitudinal models for a surrogate
marker of exposure.
Methods
Ethics Statement
Coded de-identified plasma samples were assayed for CSP- or
sporozoite-specific antibodies under a protocol approved by the
Naval Medical Research Center (NMRC) Institutional Review
Board (IRB) with a specific waiver from the IRB for the require-
ment for informed consent (protocol#NMRC.2005.0003). That
same protocol approved the use of coded de-identified plasma
samples from malaria-naı ¨ve individuals collected with written
informed consent in support of various IRB-approved NMRC
clinical studies. All procedures reported herein were reviewed and
approved by the NMRC IRB and all research was conducted in
compliance with all applicable Federal Regulations governing
protection of human subjects.
Samples
A total of 330 paired pre-deployment and post-deployment sera
were obtained from the Department of Defense Serum Repository
(White Oak, MD) corresponding to 165 of the 225 Marines of the
26
th Marine Expeditionary Unit (26
th MEU) deployed in a
holoendemic area of Liberia for 10–12 days [20]. Pre-deployment
sera were collected as part of routine health care between
November 2000 and May 2003. Post-deployment sera were
collected during the outbreak investigation between September
2003 and February 2004. Results for thick film blood slides were
available for hospitalized Marines [20].
Plasmas from 42 naı ¨ve U.S. volunteers were used as the nega-
tive comparator group and as a confirmed ‘‘unexposed’’ group.
Indirect fluorescence antibody test (IFAT)
The Indirect fluorescence antibody test (IFAT) was used to
detect antibodies against P. falciparum sporozoites. NF54 strain
sporozoites were isolated from infected Anopheles stephensi mosqui-
toes by salivary gland dissection. Sporozoites were coated on 12-
well HTC Super Cured glass slides (Cel-Line Associates, Inc.,
Newfield, NJ) at approximately 5,000 sporozoites per well, dried in
an air-locked box with desiccant and stored at 270uC. Slide wells
were blocked with 1% BSA (Sigma, St. Louis, MO). Sera were
applied in a 12-step, 2-fold dilution series beginning at a dilution
factor of 20, and incubated for 1 hour at 37uC. Slides were washed
3 times with PBS. Slide wells were stained with FITC-labeled anti-
human IgG (MP Biomedicals, Solon, OH) diluted 1:100 in 0.05%
Evans Blue-PBS and incubated at 37uC for 30 minutes. Slides
were washed as before and covered with Vectashield mounting
medium (Vector Laboratories, Inc., Burlingame, CA). Endpoint
titer was scored by fluorescence microscopy, corresponding to the
lowest dilution at which sporozoite fluorescence was observed. On
each assay day, anti-PfCSP monoclonal antibody NFS1 was
assayed in parallel as a positive control, using FITC-labeled anti-
mouse IgG (Beckton Dickenson, Franklin, NJ). The positive
control was not used for data adjustment or assay normalization.
All paired samples were read on the same day with the same batch
of coated slides.
ELISA
Enzyme-linked immunosorbant assay (ELISA) was used to
detect antibodies against recombinant P. falciparum CSP (residues
19–405). This capture antigen, produced in Escherichia coli, has
been previously described [22]. Immunolon II microtiter plates
(Dynatech Laboratory Inc., Chantilly, VA) were coated with 25 ng
recombinant CSP (3D7 strain) per well and blocked with 5%
nonfat dry milk (NFDM) in PBS. Sera were assayed at dilutions of
1/50, 1/100, 1/200 and 1/400. Data are reported for the 1/100
dilution, as this was the highest dilution with low background.
Plates were incubated with 50 mL/well HRP-labeled anti-human
IgG or IgM (Kirkegaard & Perry Laboratories, Gaithersburg, MD)
diluted 1:2000 in 3% NFDM, and developed using ABTS
substrate system (Kirkegaard & Perry Laboratories, Gaithersburg,
MD). Optical densities (OD) were recorded on a SpectraMax 190
spectrophotometer (Molecular Devices, Silicon Valley, CA) at
405 nm. NFS1 monoclonal antibody was used as a positive control
for the assay, but not for data adjustment. No inter-assay nor-
malization procedures or data adjustments were employed, except
removal of background OD from black wells, since the primary
comparison was ratio of post-exposure to pre-exposure read-outs.
Hence, paired samples were assayed on the same ELISA plates to
avoid inter-assay variation.
Exposure models
Three exposure models were tested. For a ‘‘fixed ratio’’ model, a
threshold of a post-/pre-deployment OD or endpoint titer ratio
of 2 was used to define seroconversion. A receiver-operator
characteristics (ROC) curve was constructed to test sensitivity and
specificity of variable fixed ratios. Area under the curve (AUC)
demonstrates trade-off between sensitivity and specificity; an AUC
of 1.0 is considered a perfect diagnostic model. A linear regression
model of post- vs. pre-deployment OD used ordinary least squares
(OLS) regression on data transformed using the natural logarithm,
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regression was used as the seroconversion threshold. A non-linear
regression model of non-transformed OD ratios with pre-
deployment ODs used an exponential decay equation,
y(x)~(b0{c)  e({kx)zc,
where b0 is the initial OD ratio, k is the ‘‘decay rate’’ and c is a
constant corresponding to the asymptote of the decay. As before,
the lower bound of the 95% confidence interval of the regression
line was used as the seroconversion threshold. Data demonstrating
inconstant variance across the range of measurements (hetero-
skedasticity) were re-fit using robust regression models, which are
less sensitive to violations in the assumption on constant variance.
Individuals demonstrating IgG and/or IgM seroconversion were
considered ‘‘exposed’’ according to each model.
Data analysis
Databases for both ELISA and IFAT data were managed in
Microsoft Excel 2003 and analyzed in STATA version 11
(StataCorp, LP, College Station, TX). IFAT and IgG ELISA
correlation was calculated using Pearson’s correlation coefficient
(r). Agreement between IFAT and ELISA and between exposure
models was assessed using Cohen’s kappa score. Sensitivity
analysis was performed on each model for discrimination between
exposed (hospitalized Marines) and non-exposed (naı ¨ve volunteers)
or between confirmed and suspected exposures by calculating
sensitivity, specificity, positive and negative predictive power and
likelihood ratios with 95% confidence intervals. Difference
between sensitivity and specificity of models was tested using
McNemar’s exact test, stratified by exposure group. Statistical
significance was considered for p,0.05.
Results
During the outbreak investigation, 80/225 (35.6%) of the 26
th
MEU were diagnosed with presumed P. falciparum malaria; 44
Marines were airlift evacuated and hospitalized, whilst 36 Marines
Figure 1. Patient group and sampling flowchart. Of the 225
Marines of the 26
th Marine Expeditionary Unit sent ashort to Liberia in
August, 2003, 165 serum samples were collected both prior to and after
a high incidence malaria outbreak. Of these Marines, 44 were
hospitalized with presumed malaria, of which 14 were confirmed
positive by blood smear. The non-hospitalized Marines were considered
as a cohort with undefined exposure, do to the confounding factor of
mefloquine prophylaxis or early preventive treatment. 40 naı ¨ve U.S.
adult volunteers comprised the unexposed comparator group (grey
box).
doi:10.1371/journal.pone.0021826.g001
Figure 2. Range of optical density measurements in the 26
th MEU and U.S. volunteers. The boxplot represents ranges of optical density
readings in pre- and post-deployment sera. P. falciparum positive (Pf+) and Pf2 hospitalized Marines represent the confirmed and presumed
exposure groups, respectively. Boxes are median and interquartile ranges, whiskers include outside values and dots represent outliers.
doi:10.1371/journal.pone.0021826.g002
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44 hospitalized Marines with presumed malaria, 14 (32%) had P.
falciparum positive blood slides (Figure 1).
A seropositivity threshold was defined as the mean plus three
standard deviations of the malaria-naı ¨ve comparator group (U.S.
non-exposed volunteers). This criterion was considered conserva-
tive, since the threshold is the upper limit of the 99.7% confidence
interval of the negative controls, based on a normal distribution
(Shapiro-Wilk W test for normality, p=0.07). None of the
negative controls had detectable fluorescence in the IFAT, and
all test samples which scored positive at any dilution of the IFAT
were considered seropositive. In total, 158 Marines were assayed
by sporozoite IFAT and 165 by ELISA for IgG and IgM. Ranges
of optical density readings by ELISA are shown in Figure 2. The
mean IFAT titer was 8.78 (95% CI 5.93–11.62) before deploy-
ment and 35.27 (95% CI 21.68–48.85) post-deployment. IFAT
and IgG ELISA showed poor correlation (pre-deployment r=
0.24; post-deployment r=0.59). Seropositivity in the pre-deploy-
ment sera was considered evidence of exposure before the
outbreak; 37/158 (22%) exhibited evidence of previous exposure
by IFAT and 64/165 (39%) by IgG ELISA, 5 of which were also
positive for IgM. Only one individual was positive for IgM only.
In the fixed ratio model (Figure 3A), seroconversion prevalence
was 49/158 (31%) by IFAT, 50/165 (30%) by IgG ELISA, 20 of
which also seroconverted for IgM, and 15/165 (9%) by IgM
ELISA only. A ROC curve was constructed for each test using
Figure 3. anti-CSP IgG seroconversion models applied to the 26
th MEU. P. falciparum smear positive hospitalized Marines (orange dots), P.
falciparum smear negative hospitalized Marines (green dots) and remainder of 26
th MEU (maroon dots). Fixed ratio model (A) seroconversion
threshold is post-/pre-deployment ratio of 2 (solid line). The ROC curve (B) shows sensitivity vs specificity of the fixed ratio model using
seroconversion of hospitalized Marines (exposed) against naı ¨ve U.S. volunteers (unexposed). Linear regression model (C) uses an ordinary least
squares regression line on all hospitalized marines (orange and green dots); 95% CI limits are shown in grey, positive OD threshold is shown (dashed
line) and seroconversion threshold is lower bounds of 95% CI limits. The exponential decay model (D) uses a non-linear negative exponential
regression line on all hospitalized Marines (orange and green dots); 95% CI limits are shown in gray and seroconversion threshold is lower 95% CI
limits. Data for IgM ELISA and sporozoite IFAT are not shown.
doi:10.1371/journal.pone.0021826.g003
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ized Marines as the ‘‘exposed’’ group (Figure 3B). AUC was 0.68
(95% CI 0.57–0.80) for IFAT, 0.85 (95% CI 0.76–0.94) for IgG
ELISA and 0.89 (95% CI 0.81–0.97) for IgM ELISA. The fixed
ratio model predicted that 56/158 (35%) of Marines were exposed
by IFAT and 65/158 (39%) by ELISA. Agreement between IFAT
and IgG ELISA was 84% (kappa score: 0.62, p,0.0001).
To account for pre-existing antibody on antibody reactivity
following exposure, regression models were used to establish
dynamic seroconversion thresholds. Linear regression models
(Figure 3C) returned seroconversion prevalence of 37/165 (22%)
IgG only, 33 (20%) both IgG and IgM, and 8/165 (5%) IgM only.
Prediction of exposure in the 26
th MEU was 74/165 (45%). To
control for the magnitude of change between pre- and post-
deployment antibodies, nonlinear regression on OD ratios vs. pre-
deployment OD was fitted (Figure 3D). Seroconversion prevalence
was 34/165 (21%) IgG only, 31/165 (19%) both IgG and IgM,
and 9/165 (5%) IgM only. Exposure was predicted in 74/165
(45%) of the 26
th MEU.
Agreement between the two regression models was 95% (kappa
score: 0.90, p,0.0001), and agreement between the fixed ratio
model and linear or nonlinear regression was 87% (kappa score:
0.74, p,0.0001) and 92% (kappa score: 0.84, p,0.0001), re-
spectively. The ability of each model to discriminate between
individuals with presumed exposure or none was similar, with
overlapping confidence intervals in all measurements of sensitivity,
specificity, positive and negative predictive values, and likelihood
ratios (Table 1), and no method showed difference in proportion of
exposures (marginal homogeneity, exact p.0.05). All models
showed lower specificity when discriminating between hospitalized
Marines with positive or negative blood smears. No method
showed significant differences in this comparison (marginal homo-
geneity, exact p.0.05).
Discussion
An outbreak of P. falciparum malaria among U.S. Marines
provided an opportunity to investigate a surrogate marker of
exposure in a cohort with variable exposure history. Indeed,
many of the 26
th MEU were seropositive to CSP prior to
deployment in Liberia, unsurprising, since many of them were
likely deployed previously in malaria endemic areas. Adherence to
chemoprophylaxis provided before deployment, among other
preventive measures, was believed to be low, although adherence
could be a confounding factor in assessment of exposure. Only a
third of the hospitalized Marines gave a positive blood slide, which
may be explained by antimalarial therapy of febrile Marines
before definitive laboratory testing [20]. Regardless, the clinical
characteristics of the outbreak lead us to suspect that the entire
group of hospitalized Marines was exposed to malaria.
Multiple models were tested to find the most suitable for a
surrogate marker of exposure. However, the data from this cohort
do not highlight any superior model. The fixed ratio model is
practical, but may be best applied to travelers or those with little
history of exposure, as antibody responses in pre-exposed indi-
viduals increase less dramatically after exposure. Indeed, sensitivity
of the fixed ratio model seemed slightly higher for the IFAT when
comparing only those marines without evidence of pre-exposure
against controls (sensitivity: 70.0%, 95% CI 50.6–85.3%), al-
though the sensitivity by ELISA did not change. For studies in
malaria endemic populations, a regression model that controls
for baseline antibodies would be more appropriate. The models
employed here must be tested in populations under different
exposure patterns. A limitation of these data is the large range of
time between outbreak and blood sample collection. Given short
antibody half-lives, detection may have been dampened by loss of
reactivity [13]. Additionally, some individuals with confirmed
exposure had no anti-CSP antibody response. The most severe
malaria case showed no antibodies to CSP. This is consistent with
other studies that have noted absent antibody responses following
severe malaria infection [23]. Inclusion of additional antigens to
control for heterogeneity in antibody responsiveness may increase
the robustness of such models.
These models may help in distinguishing protection from lack of
exposure in assessment of interventions. The high positive pre-
dictive value observed in these data suggests that the ‘‘exposures’’
were correctly classified. Improvements to the models must be
made before ‘‘unexposed’’ groups may be classified due to lower
negative predictive values (Table 1). Data from additional pre-
erythrocytic antigens should be fitted as well, since the utility of
CSP may be compromised if a licensed vaccine such as RTS,S is
employed [24], and the disagreement between ELISA and IFAT
suggests that additional sporozoite antigens may be present.
Table 1. Diagnostic sensitivity analysis of exposure models by comparison group.
Model Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) LR+
b (95% CI) LR2
b (95% CI)
26
th MEU with presumed exposure
a vs. naı ¨ve U.S. volunteers
Fixed ratio: IFAT 58.1 (42.1–73.0) 90.6 (75.0–98.0) 89.3 (71.8–97.7) 61.7 (46.4–75.5) 6.2 (2.1–18.8) 0.5 (0.3–0.7)
Fixed ratio: ELISA 67.4 (51.5–80.9) 87.5 (71.0–96.5) 87.9 (71.8–96.6) 66.7 (50.5–80.4) 5.0 (2.1–13.8) 0.4 (0.2–0.6)
Linear regression 69.8 (53.9–82.8) 96.9 (83.8–99.9) 96.8 (83.3–99.9) 70.5 (54.8–83.2) 22.3 (3.2–155.2) 0.3 (0.2–0.5)
Nonlinear regression
b 67.4 (51.5–80.9) 96.9 (83.8–99.9) 96.7 (82.8–99.9) 68.9 (53.4–81.8) 14.8 (3.1–71.4) 0.4 (0.2–0.5)
26
th MEU with confirmed exposure (P. falciparum smear positive) vs. presumed exposure (P. falciparum smear negative)
Fixed ratio: IFAT 64.3 (35.1–87.2) 44.8 (26.4–64.3) 36.0 (18.0–57.5) 72.2 (46.5–90.3) 1.2 (0.7–1.9) 0.8 (0.4–1.8)
Fixed ratio: ELISA 85.7 (57.2–98.2) 41.4 (23.5–61.1) 41.4 (23.5–61.1) 85.7 (57.2–98.2) 1.5 (1.0–2.1) 0.35 (0.1–1.3)
Linear regression 85.7 (57.2–98.2) 37.9 (20.7–57.7) 40.0 (22.7–59.4) 84.6 (54.6–98.1) 1.4 (1.0–2.0) 0.4 (0.1–1.5)
Nonlinear regression
b 78.6 (49.2–95.3) 37.9 (20.7–57.7) 37.9 (20.7–57.7) 78.6 (49.2–95.3) 1.2 (0.8–1.9) 0.6 (0.2–1.7)
NOTE. IFAT: immunofluorescence assay test; ELISA: enzyme-linked immunosorbent assay; PPV: positive predictive power; NPV: negative predictive power; LR: likelihood
ratio.
a43 hospitalized Marines diagnosed with P. falciparum malaria according to clinical criteria.
bLikelihood ratios estimated using the substitution formula (0.5 added to all 262 table frequencies).
doi:10.1371/journal.pone.0021826.t001
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data sets, these data lay groundwork for subsequent studies of
surrogate markers of exposure. The complexity of the immune
response to malaria warrants further modeling of antibodies, and
we plan to continue development of these models by testing them
in well-characterized malaria endemic populations and using
additional antigens, including commercially produced peptides. It
is likely that important variables are missing from the regression
models, such as age and time since exposure. Future modeling
exercises should attempt to control for these variables.
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